Drug Profile
RBM 008
Alternative Names: RBM-008Latest Information Update: 26 Jun 2023
Price :
$50
*
At a glance
- Originator Ribomic
- Class Eye disorder therapies; Nucleotide aptamers
- Mechanism of Action Cell adhesion molecule inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Diabetic retinopathy
Most Recent Events
- 23 Jun 2023 Discontinued - Preclinical for Diabetic retinopathy in Japan (unspecified route) (Ribomic pipeline, June 2023)
- 15 Jul 2021 Preclinical development for Diabetic retinopathy is ongoing in Japan (Ribomic pipeline, July 2021)
- 28 Aug 2020 No recent reports of development identified for preclinical development in Diabetic-retinopathy in Japan